Company intelligence / Profile preview

Cardiff Oncology

San Diego, California, United Statescardiffoncology.com ↗

Ownership: Public · CRDF
Employees: ~31
Development stage: Phase 2

Overview

Cardiff Oncology’s lead asset, onvansertib—a selective PLK1 inhibitor—is being evaluated in combination with standard-of-care therapies. In the ongoing randomized Phase 2 CRDF-004 trial for first-line RAS-mutated mCRC, initial results showed a 64% objective response rate (ORR) at the higher dose of onvansertib versus 33% ORR in the control arm. The drug was well tolerated and demonstrated deeper tumor regression at higher doses. Additional data are expected in H1 2025[7][9]. The company has secured new patents extending IP protection through at least 2043 and has raised $40M to support further development[7][8].

Therapeutic areas: Oncology
Modalities: Small molecules (PLK1 inhibitor)
Industry: Biotech

Drug pipeline

1 asset

onvansertib

Partnerships

No major pharma partnerships disclosed as of May 2025.

Financials

Market cap: $93.3M
Total revenue: $104K
Enterprise value: $59.2M

Beyond the preview

Go deeper on Cardiff Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiff Oncology.

Explore the full profile